Maria Contreras
Pediatric Endocrinology · Amarillo, TXNPI 1467736363
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,445 of the $1,806 with a category attached, or 80.0%. 25 manufacturers reported payments, led by Medtronic at 31.1% of the total. 2025 is the largest year on record at $843, 4.9 times the $171 reported in 2019.
Across 58 payments — averaging $31.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$562
- Abiomed$206
- Insulet Corporation$175
- Neurocrine Biosciences, Inc.$128
- Sanofi-aventis U.S. LLC$107
- Rhythm Pharmaceuticals, Inc.$87
- plus $541 from 19 others
Across 259 payments — averaging $1142.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$116K
- Rhythm Pharmaceuticals, Inc.$95K
- Pfizer$85K
What the payments were for
- Travel & lodging$33719%
- Food & beverage$1,44580%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 11 | $562 |
| Abiomed | 3 | $206 |
| Insulet Corporation | 5 | $175 |
| Neurocrine Biosciences, Inc. | 5 | $128 |
| Sanofi-aventis U.S. LLC | 2 | $107 |
| Rhythm Pharmaceuticals, Inc. | 4 | $87 |
| Xeris Pharmaceuticals, Inc. | 3 | $46 |
| Ascendis Pharma Endocrinology Inc | 2 | $44 |
| Sequel Med Tech, LLC | 1 | $38 |
| Tolmar, Inc. | 2 | $36 |
| Endo Pharmaceuticals Inc. | 2 | $36 |
| Pfizer | 2 | $35 |
| Biomarin Pharmaceutical Inc. | 2 | $35 |
| Tolmar Pharmaceuticals, Inc. | 2 | $34 |
| Soleno Therapeutics, Inc. | 1 | $34 |
| Dendreon Pharmaceuticals LLC | 1 | $30 |
| Novo Nordisk | 1 | $25 |
| AbbVie | 1 | $23 |
| Eton Pharmaceuticals, Inc. | 1 | $23 |
| AstraZeneca | 2 | $22 |
| Endo USA, Inc. | 1 | $20 |
| Tandem Diabetes Care, Inc. | 1 | $17 |
| BETA Bionics, Inc. | 1 | $16 |
| Abbott | 1 | $16 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$256
- Impella$143
How this compares
$1,806 in reported general payments places this provider in the 60th percentile of 120 pediatric endocrinology providers in Texas.
Other pediatric endocrinology in Amarillo
- Jose Gamez-GodoyEdinburg$207K
- Virginia AraizaHouston$151K
- Daniel DesalvoHouston$133K
- Amy BurtonPlano$130K
- Susan NunezAustin$91K
- Hector GranadosEl Paso$73K
- Donnie WilsonFort Worth$58K
- Paul ThorntonFort Worth$52K
- Jane LynchSan Antonio$44K
- Steven WaguespackHouston$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.